We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01078337
First Posted: March 2, 2010
Last Update Posted: March 2, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Stanford University
  Purpose
To determine if MRD (minimal residual disease) can be found in the blood (only) as opposed to bone marrow in children with ALL (acute lymphoblastic leukemia).

Condition Intervention
Leukemia, Lymphocytic, Acute Procedure: bone marrow aspiration Procedure: peripheral blood sampling

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: T-cell MRD Evaluation Using Flow Cytometric Analysis

Resource links provided by NLM:


Further study details as provided by Stanford University:

Biospecimen Retention:   Samples With DNA
blood and bone marrow

Estimated Enrollment: 15
Study Start Date: November 2002
Study Completion Date: October 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
children with newly diagnosed T-cell ALL
Criteria

Inclusion Criteria:

  • Children with newly diagnosed T-cell ALL
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01078337


Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Gary V Dahl Stanford University
  More Information

Responsible Party: Gary V Dahl, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT01078337     History of Changes
Other Study ID Numbers: SU-11022007-790
PEDSALL0001
First Submitted: February 26, 2010
First Posted: March 2, 2010
Last Update Posted: March 2, 2010
Last Verified: February 2010

Additional relevant MeSH terms:
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasm, Residual
Leukemia
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplastic Processes
Pathologic Processes